Clinical trials: Solid Malignant Tumor
Unspecified Adult Solid Tumor, Protocol Specific
3-AP in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of 3-AP in treating patients who have advanced cancer.
- Trial name
- NCT00006218
- Testing
- triapine
- Where
- United States
- Sponsor
- Vion Pharmaceuticals
Advanced Solid Tumors
Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors
The goal of this clinical trial is to evaluate the safety, tolerance, pharmacokinetics, and biological properties of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced solid…
- Trial name
- NCT05914376
- Testing
- Recombinant human IL-21-expressing oncolytic vaccinia virus injection
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Hangzhou Converd Co., Ltd.
TMB-H, Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
The goal of this clinical trial is to determine the efficacy of IMC-001 in metastatic or locally advanced TMB-H solid tumor patients.
- Trial name
- TMB-H (NCT06365840)
- Testing
- IMC-001
- Where
- 4 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- ImmuneOncia Therapeutics Inc.
Solid Tumor, Adult
Study of FCN-437c in Patients With Advanced Solid Tumors
This research study is studying a drug called FCN-437c as a possible treatment for patients with advanced unresectable/metastatic solid tumors.
- Trial name
- FCN-437c (NCT03951116)
- Testing
- FCN-437
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Fochon Pharmaceuticals, Ltd.
Malignant Lymphoma of Extranodal and/or Solid Organ Site, Solid Tumor
Safety Study of Camptothecin-20-O-Propionate Hydrate (CZ48)
This is a single-arm, non-randomized feasibility and Phase I trial of 20(S) Camptothecin Propionate administered orally. CZ48 will be administered in successive cohorts of 1 patient per participating site until hints of toxicity…
- Trial name
- NCT02575638
- Testing
- CZ48
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Cao Pharmaceuticals Inc.
Advanced Solid Tumor
Study of RP-3500, Camonsertib, in Advanced Solid Tumors
The primary purpose of this study is to define the maximum tolerated dose (MTD) and determine a recommended Phase 2 dose (RP2D) and schedule of orally-administered RP-3500 (camonsertib) alone or in combination with talazoparib, a…
- Trial name
- TRESR (NCT04497116)
- Testing
- RP-3500 (camonsertib), Talazoparib, Gemcitabine Injection
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 276 people
- Sponsor
- Repare Therapeutics
Advanced Solid Tumor
The Absorption, Metabolism and Excretion of [14C]CM082 in Human
This is a single-center, open-label, single-dose phase I study to investigate the absorption, metabolism and excretion of [14C] CM082 in healthy Chinese male subjects.
- Trial name
- NCT04434326
- Testing
- [14]CM082 suspension
- Where
- China
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- AnewPharma
Advanced Solid Tumor
Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors
This project is a phase Ib clinical trial study evaluating the efficacy and safety of TQB2618 injection combined with TQB2450 injection in patients with advanced solid tumors, the trial plan to enroll 127 subjects, the trial…
- Trial name
- NCT05645315
- Testing
- TQB2618 injection and TQB2450 injection
- Where
- 5 sites in China
- Volunteers
- 127 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Solid Tumor
A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor
This study is a phase I/II study of single drug TJ011133 and Toripalimab combine treatment forAdvanced solid tumor. This study include two stages. First stage is dose escalation and second stage is dose extension.
- Trial name
- NCT05148533
- Testing
- TJ1133 Injection
- Where
- 22 sites in China
- Volunteers
- 7 people
- Sponsor
- TJ Biopharma Co., Ltd.
Solid Tumor, Lung Cancer
A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
This is a multi-center, multi-cohort, open-label, phase Ib/II study to evaluate the efficacy, safety, PK characteristics, immunogenicity and potential biomarkers of AK105 monotherapy in the patients with selected advanced solid…
- Conditions
- Solid Tumor, Lung Cancer, HCC
- Trial name
- NCT04172506
- Testing
- AK105
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Akeso
Advanced Malignant Solid Tumor
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
This study is investigating a new experimental therapy, MP0317, a DARPin® drug candidate targeting fibroblast activation protein (FAP) and CD40.
- Trial name
- NCT05098405
- Testing
- MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen), MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)
- Where
- 4 sites in France, Netherlands
- Volunteers
- 46 people
- Sponsor
- Molecular Partners AG
Neoplasm
MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)
The purposes of this phase I portion are; 1) to evaluate the safety and tolerability of MK2461 and 2) to determine the recommended phase 2 dose or doses of MK2461.
- Trial name
- NCT00496353
- Testing
- MK2461
- Volunteers
- 26 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer, Breast Cancer
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
- Trial name
- NCT06533059
- Testing
- ALTA2618
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 110 people
- Sponsor
- Alterome Therapeutics, Inc.
Hepatocellular Carcinoma, Renal Cell Carcinoma
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread.
- Conditions
- Hepatocellular Carcinoma, Renal Cell Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Carcinoma Primary Differentiated
- Trial name
- NCT07252661
- Testing
- ACC-1898
- Volunteers
- 40 people
- Sponsor
- AccSalus Biosciences, Inc.
Metastatic Melanoma and Other Solid Tumors
A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer
Researchers are looking for a better way to treat people who have advanced cancer. In this study researchers want to learn more about a new substance called BAY2666605.
- Trial name
- NCT04809805
- Testing
- BAY2666605
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Bayer
Malignant Solid Tumors
PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy
The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lung cancer,head and neck cancer,colorectal cancer,and ovarian cancer receiving multi-cycle chemotherapy.
- Trial name
- NCT02805166
- Testing
- PEG-rhG-CSF
- Volunteers
- 420 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Epithelial Ovarian Cancer, Peritoneal Cancer
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
The purpose of this study is to determine the biologically active dose of entinostat, when given in combination with avelumab, that is safe and warrants further investigation.
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT02915523
- Testing
- entinostat, avelumab
- Where
- 12 sites in United States
- Volunteers
- 140 people
- Sponsor
- Syndax Pharmaceuticals
Solid Tumor, TNBC - Triple-Negative Breast Cancer
TH1902 in Patients With Advanced Solid Tumors
Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard…
- Conditions
- Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT04706962
- Testing
- TH1902
- Where
- 6 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Theratechnologies
Solid Tumors
A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors
This study was planned to evaluate the safety and tolerability of RO7296682 in participants with advanced solid tumors.
- Trial name
- NCT04158583
- Testing
- RO7296682
- Where
- 11 sites in Australia, Belgium and 3 more
- Volunteers
- 76 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
Study of Oral Darinaparsin in Patients With Advanced Solid Tumors
This study is a Phase I, dose escalation study of oral darinaparsin for the treatment of advanced solid tumors. Eligible patients could have received any amount of previous therapy.
- Trial name
- NCT01139346
- Testing
- darinaparsin
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Alaunos Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.